Stellate Ganglion Block and Prognosis of Neurological Function After Subarachnoid Hemorrhage

June 11, 2026 updated by: Ruquan Han, Beijing Tiantan Hospital

Effect of Stellate Ganglion Block on the Prognosis of Neurological Function After Subarachnoid Hemorrhage

The incidence of cerebral vasospasm after aneurysm subarachnoid hemorrhage (aSAH) is as high as 70%; cerebral vasospasm（CVS） is closely related to delayed cerebral ischemia （DCI）, which is one of the important reasons for poor outcomes in patients with aSAH.

In recent years, it has been reported that stellate ganglion block(SGB) can effectively alleviate cerebral vasospasm(CVS), reduce cerebral blood flow velocity and increase cerebral perfusion in patients with aneurysm subarachnoid hemorrhage(aSAH)。However, whether the alleviation of CVS after SGB is beneficial to the long-term neurological prognosis has not been confirmed Therefore, a prospective randomized controlled study is needed to further explore the role of SGB block in improving the outcomes of patients with aSAH.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

560

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100070
        • Beijing Tiantan Hospital, Capital Medical University
        • Contact:
        • Principal Investigator:
          • Ruquan Han, M.D., Ph.D

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age range: 18-65 years old;
  • Within 72 hours after onset of aSAH,and planning surgical treatment(aneurysm embolizing or clipping);
  • Preoperative Hunt-Hess grade 2-3
  • Sign informed consent.

Exclusion Criteria:

  • ASA > grade IV;
  • Patients with posterior circulation aneurysm;
  • Patients with severe systemic hemorrhagic diseases;
  • Patients with trauma and local infection in the nerve block area;
  • Local anatomic structure changes (neck structure changes caused by radiotherapy, chemotherapy and surgery);
  • Allergy to known local anesthetics;
  • Pregnant and lactating women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
In addition to routine anesthesia management and surgical operations, an ultrasound-guided stellate ganglion block was performed once prior to the initiation of surgery, and then receive standard care after operation. Related statistical indicators were collected prospectively.
Procedure: Intervention group
Prior to the initiation of surgery, a single ultrasound-guided stellate ganglion block was performed on the ipsilateral side of the lesion.The dose and concentration of local anesthesia: 0.5% ropivacaine 5-10ml. Criteria for successful block: the patient developed Horner's syndrome, characterized by miosis, ptosis, eyeball caved in, nasal congestion, conjunctival congestion, reddish face and no sweat on the face
Other Names:
  • Stellate ganglion block
No Intervention: Blank control group
In this study, a blank control was used. Routine anesthesia management and surgical operation were used without any special interventions, and then receive standard care after operation. Only relevant statistical indicators were collected prospectively.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The modified Rankin Scale (mRS) scores at 90 days
Time Frame: 90 days postoperatively
The modified Rankin Scale (mRS) is used to evaluate the primary outcome. The scale of mRS is 0 to 6. The best neurological outcome is the mRS with 0, indicating no any symptom left. mRS of 6 is the worst, indicating death. mRS will be evaluated by outcomes assessor who is blinded to the grouping.
90 days postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incidence of delayed cerebral ischemia (DCI) during hospitalization
Time Frame: At discharge, an average of 2 weeks
At discharge, an average of 2 weeks
All cause mortality during 90 days after onset
Time Frame: 90 days postoperatively
90 days postoperatively
Length of stay in the intensive care unit and hosipital
Time Frame: At discharge, an average of two weeks
At discharge, an average of two weeks
Adverse events during hospitalization
Time Frame: At discharge, an average of 2 weeks
Myocardial infarction, cardiac arrest, pulmonary embolism, infection, SGB related complications, etc
At discharge, an average of 2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Beijing Tiantan Hospital

Investigators

  • Principal Investigator: Ruquan Han, M.D., Ph.D, Beijing Tiantan Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 15, 2026

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

March 31, 2029

Study Registration Dates

First Submitted

March 2, 2021

First Submitted That Met QC Criteria

June 11, 2026

First Posted (Actual)

June 17, 2026

Study Record Updates

Last Update Posted (Actual)

June 17, 2026

Last Update Submitted That Met QC Criteria

June 11, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Z191100006619069

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aneurysmal Subarachnoid Hemorrhage

Clinical Trials on Intervention group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe